Precision Medicine in Alzheimer’s Disease – Neuroimaging
Time: 11:30 am
day: Clinical & Commercial Track AM
Details:
- Discuss how Amyloid and Tau imaging have contributed to development of the Biomarker-driven NIA-AA framework that classifies individuals in an unbiased symptom-agnostic fashion based on key AD-pathophysiological changes
- Provide specific examples for Tau and Amyloid PET imaging in the NIA-AA context
- Deep dive into Amyloid PET with NAV4694
